CKD burden continue to remain high in the United States and Medicare spending for all beneficiaries who had CKD exceeded $79 billion in 2016. The 2019 Chronic Kidney Disease issue of NephSAP guides readers through the latest advances in clinical research for this common and costly disease. This issue of NephSAP provides a background of the clinical research published during the years 2017 and 2018, and covers several major areas of CKD research: epidemiology, biomarkers relevant to incidence and progression, genetic variants, cardiovascular disease, weight loss interventions, and novel tools to improve CKD care measures. There have been exciting developments in our understanding of the pathogenesis and treatment options for diabetic kidney disease in the recent years. Several relevant clinical trials that demonstrated improvements in outcomes for those with diabetic kidney disease have been highlighted in this issue. Along with it, several novel risk factors for progression of kidney disease have also been discussed. Cardiovascular disease remains the principal cause of death for adults with CKD. This NephSAP outlines advances in management of atrial fibrillation and the use of device therapy in CKD. The epidemiology and conseqeuences of pulmonary hypertension, peripheral artery disease and congnitive function in those with CKD are also discussed. Clinical practitioners will also be provided with insight into topics ranging from management of obesity along with understanding about novel methodology and tools that have been tested to help improve CKD care delivery. Finally, readers can also test their knowledge with a series of 30 questions.